Mergers & acquisitions
The people at Eloxx Pharmaceuticals share a common goal — to bring safe and effective therapies to children and adults suffering from rare genetic diseases as quickly as possible.
Alexion Pharmaceuticals is buying Wilson Therapeutics for $855 million. With the company, Alexion will acquire WTX101, Wilson Therapeutics’ Phase III compound for Wilson disease.
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Swiss pharma giant Roche has had an active April so far. The company has acquired a multiple sclerosis program, completed the acquisition of a company and secured a big win with the United Kingdom’s healthcare provider for lung cancer drug Tecentriq.
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
Shares of Shire Plc spiked overnight after increased rumors that Japanese pharma giant Takeda could be closer to making a deal to acquire the rare disease company.
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
Building on a four-year-old relationship Roche struck a deal to acquire a regenerative therapy program for multiple sclerosis from Inception Sciences, a drug discovery engine co-founded with Versant Ventures in 2011.
Pfizer Inc. may have a new potential buyer for its consumer health business unit. Mega-consumer goods company Procter & Gamble is reportedly interested in acquiring the business.
Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
PRESS RELEASES